Skip to main content
Premium Trial:

Request an Annual Quote

BioPAL Awarded $100K SBIR Grant to Develop Diagnostics Based on Isotope-labeled Probes

NEW YORK, June 14 (GenomeWeb News) - BioPhysics Assay Laboratory (BioPAL) has been awarded a Phase I Small Business Innovation Research grant from the National Center for Research Resources to develop diagnostics based on stable isotope-labeled functional probes, the company said today.


BioPAL said the technology under development is "an automated accelerator-based neutron generation device" that will quantify the presence of stable isotope-labeled physiological probes in biological samples "without interference from the sample matrix."


BioPAL currently markets several stable isotope-labeled physiological probes, such as microspheres for blood flow studies and nanocolloids for cell labeling and tracking, but said that samples under investigation currently have to be returned to the firm to be assayed in a large, fixed neutron generator.


The SBIR grant will enable BioPAL to develop a compact device that could be installed at a researcher's institution, the company said.


The firm did not disclose the amount of the award, but an NIH database lists the company as a recipient for a $99,644 award entitled, "An Accelerator-Based Neutron Activation Device."


BioPAL said that it has been awarded more than $3 million in SBIR grants. The Worcester, Mass.-based company was founded in 1997.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.